{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+%2F+HER2-negative+Breast+Cancer&page=7", "query": { "condition": "Hormone Receptor Positive / HER2-negative Breast Cancer", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 225, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+%2F+HER2-negative+Breast+Cancer&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+%2F+HER2-negative+Breast+Cancer&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T03:59:32.660Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06369285", "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2024-11-19", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06369285" }, { "nct_id": "NCT05646862", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-06-07", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 39, "location_summary": "Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05646862" }, { "nct_id": "NCT05549505", "title": "A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ARV-471", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Surgical resection of breast tumor", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2023-02-15", "completion_date": "2024-07-25", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Van Nuys", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549505" }, { "nct_id": "NCT03393845", "title": "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nancy Chan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2018-01-29", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 5, "location_summary": "Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Lansing", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393845" }, { "nct_id": "NCT03477396", "title": "Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor and/or Progesterone Receptor Positive", "HER2/Neu Negative", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 2, "start_date": "2018-06-14", "completion_date": "2023-06-05", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 9, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 6 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03477396" }, { "nct_id": "NCT06525766", "title": "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen-receptor-positive Breast Cancer", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-01", "completion_date": "2030-10-15", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525766" }, { "nct_id": "NCT03723928", "title": "S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8", "Elevated CA15-3 or CEA or CA27-29" ], "interventions": [ { "name": "Usual care disease monitoring", "type": "OTHER" }, { "name": "Serum Tumor Marker directed disease monitoring", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Anxiety Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 739, "start_date": "2018-09-17", "completion_date": "2036-12-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 709, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03723928" }, { "nct_id": "NCT04274933", "title": "A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-05-21", "completion_date": "2020-10-08", "has_results": false, "last_update_posted_date": "2020-10-29", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 11, "location_summary": "Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Joliet", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274933" }, { "nct_id": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "VS-6766", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2023-02-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608252" }, { "nct_id": "NCT05207709", "title": "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib + Letrozole OR Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib + Letrozole OR Fulvestrant", "type": "DRUG" }, { "name": "Paclitaxel +/- Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOLTI Breast Cancer Research Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-03-28", "completion_date": "2026-03-26", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-31T03:59:32.660Z", "location_count": 26, "location_summary": "Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207709" } ] }